What identity data should a CJC-1295 supplier Australia provide on each lot?
A defensible identity file for CJC-1295 starts with an unambiguous statement of the molecular construct. In the primary chemistry literature, CJC-1295 was identified as a GRF analogue assembled as an hGRF(1-29)–albumin bioconjugate (PMID:15817669). Research suppliers operating in Australia should state whether a given lot is the maleimide-bearing albumin-binding construct or a related tetrasubstituted GRF(1-29) sequence that lacks the conjugation handle. Those materials do not share the same intact mass, reversed-phase retention or impurity map, yet they are often listed under overlapping catalogue names. If the supplier cannot say which construct was synthesised, identity has not been specified. Identity evidence should be orthogonal: a declared sequence or modification scheme; theoretical monoisotopic and average masses for the stated counter-ion form; an intact electrospray mass spectrum with a coherent charge-state envelope; and a reversed-phase HPLC retention time under a documented method. Matching a single observed m/z to a web calculator is not sufficient, because isobaric deletion sequences, incomplete deprotection products and truncated GHRH fragments can fall inside a wide mass window if resolution and mass accuracy are unreported. Work on unknown pharmaceutical preparations has shown that CJC-1295 can be identified in unlabelled material once suitable chromatography and mass spectrometry are applied (PMID:21204297). The name on a cap is not an identity test. Require the vial lot number to match the CoA, and archive spectral figures rather than a one-line identity-confirmed statement. Counter-ion and water change the mass of the solid, so a high area-percent figure without those values does not define peptide content. Retain chromatograms and spectra with the purchase record so the chemical definition can be reconstructed later.
How should reversed-phase HPLC purity be read on a CJC-1295 CoA?
Reversed-phase HPLC with ultraviolet detection remains the usual purity assay for synthetic GHRH analogues, but the printed purity figure is method-defined. For each CJC-1295 lot, record column chemistry (typically C18 or C8), particle and pore size, mobile-phase pair (water/acetonitrile with trifluoroacetic or formic acid), gradient table, flow rate, column temperature, detection wavelength and the integration threshold. Changing any parameter can merge or split related substances and move the main-peak percentage. Peak purity is not chromatographic purity. Chromatographic purity is main-peak area divided by summed integrated area. Diode-array algorithms can flag co-elution when a chromophore is present; they do not identify the co-eluting species. Related substances in this class include deletion sequences, incomplete deprotection products, oxidation or isomerisation products where the sequence allows them, and residual conjugation-handle species if a maleimide linker was used. A CoA stating related substances not detected without a reporting threshold or chromatogram is not interpretable. System suitability should be visible: a blank, a resolution check or a reference chromatogram, and a retention window for the main peak. If a contract laboratory performed the work, name that laboratory and the method identifier. Integration parameters should be stable across lots, or purity comparisons become numerical artefacts. Do not confuse area-percent with peptide content. Water, residual solvents and counter-ions add mass that peptide-selective UV may not see. Karl Fischer water and a counter-ion assay allow net peptide content to be calculated, which is the only fair basis for comparing Australian unit prices. State whether purity is as-is or anhydrous and counter-ion-corrected.
Which orthogonal mass-spectrometric methods confirm CJC-1295 identity?
Intact-mass electrospray ionisation mass spectrometry is the first orthogonal check on HPLC-UV purity. A usable spectrum of a CJC-1295-class peptide should show a coherent charge-state envelope, deconvolute to a mass consistent with the declared sequence and modification, and state the resolution and mass-accuracy window. A single nominal mass without charge-state assignments leaves room for a different sequence with a similar residue sum. High-resolution data make the monoisotopic peak assignable; unit-resolution quadrupole traces should at least display several charge states. Tandem mass spectrometry adds sequence evidence through b- and y-ion series and, where a maleimide handle is declared, fragments that localise that modification. Published confirmatory work has used LC-MS/MS to distinguish CJC-1295 from related GHRH analogues in complex matrices (PMID:30938069). Research-reagent CoAs do not need forensic matrix methods, but they should still show intact mass and, preferably, diagnostic fragments. A UV peak without a mass spectrum is not identity confirmation. Selective enrichment in the bioanalytical literature makes the same point. Immunoaffinity purification of peptide hormones before LC-MS has been used to raise selectivity for peptide analytes (PMID:21871962). An immuno-polymerase-chain-reaction screen has been reported for CJC-1295 and other GHRH analogues in equine plasma (PMID:30489688). Those workflows are not a CoA template; they show that published methodology treats the compound as a discrete chemical entity. An Australian research supplier meets the analogous requirement by providing the HPLC chromatogram and the ESI or LC-MS dataset for the same lot, with method parameters. Unexplained extra masses, or screenshots without axes, are documentation defects. This remains characterisation of a research chemical.
What do published GHRH-analogue detection papers imply for quality control?
The analytical literature on synthetic GHRH analogues helps procurement even when methods were built for biological matrices. A 2021 review of advances in detecting growth-hormone-releasing hormone synthetic analogues summarises how laboratories differentiate this structural family (PMID:34665524). Analogues that share much of the GRF(1-29) backbone can co-elute or share fragment ions if methods are not designed to resolve them. That matters in a catalogue where CJC-1295, tetrasubstituted GRF(1-29) without a conjugation handle, tesamorelin-class constructs and truncated fragments may appear under similar names. Confirmatory LC-MS/MS methods for CJC-1295 establish identity by retention plus multiple mass-spectrometric transitions, not by one detector response (PMID:30938069). Screening layers such as immuno-PCR have been used to triage samples before confirmatory mass spectrometry (PMID:30489688). Immunoaffinity capture before LC-MS is a further selectivity tool (PMID:21871962). A vendor CoA should not copy those matrix methods. The transferable hierarchy is that UV-only or immunoassay-like signals are screening-level, whereas mass-accurate intact mass and fragment ions are confirmatory. Accepting a purity percentage with no mass spectrum stops at screening. Published papers state column, gradient, precursor and product ions, and specificity against related analogues. A research supplier can mirror that transparency by listing HPLC conditions, observed mass and any confirmatory ions. Lots sold as the same catalogue item should be analytically comparable; unexplained shifts in retention or mass suggest an undocumented construct or method change. Phrases such as pharmaceutical grade or a rounded purity claim are not methods. Keep the scope chemical: matrix detection papers are cited only as identity-evidence benchmarks, not as sampling guidance.
Which batch-documentation fields should Australian laboratories require?
Lot traceability separates a research reagent from an anonymous solid. Each vial should carry a lot number reproduced on the CoA, the HPLC report and the mass-spectrometry report. Multi-vial orders filled from more than one lot need a file per lot. Dates of synthesis or receipt, dates of testing, and the testing laboratory’s identity allow a check that the data belong to the material on the bench. A practical Australian pack for CJC-1295 includes appearance of the lyophilised solid; declared quantity per vial and its basis (as-is versus net peptide); counter-ion; water content; HPLC purity with chromatogram; intact mass or LC-MS identity; related-substance comments; residual solvents if claimed; and labelled storage for the dry solid. Tracked dispatch from local stock, with the lot number on the consignment note and a carrier tracking number, closes the chain from warehouse to bench. Method identifiers should appear so re-orders remain comparable if gradients or mass-spectrometer settings change. Chromatograms need readable axes, integration marks and sample codes; redacted reports that omit the sample identifier cannot be tied to the vial. Research peptides offered as laboratory reagents are not therapeutic goods, and a CoA is not a product registration or clinical release certificate. Endotoxin or bioburden figures, if present, must name the method and reporting limit; if absent, treat them as not assessed. Archive PDFs with the purchase order and a photograph of the vial lot label, plus a research-use-only statement aligned with the supplier’s terms. That file is what makes the supplier auditable when a later experiment needs the same chemical definition.
How can laboratories compare CJC-1295 suppliers without relying on catalogue names?
Catalogue names collapse several chemical realities into one string. One listing may mean the albumin-bioconjugate construct identified in the GRF analogue literature (PMID:15817669); another may mean tetrasubstituted GRF(1-29) without a conjugation handle; a third may mean a different GHRH analogue entirely. Unknown preparations have been shown to contain CJC-1295 only after instrumental identification (PMID:21204297). Shopping by name therefore compares labels, not substances. Ask for the declared sequence or modification, theoretical mass, observed deconvoluted mass, and a chromatogram from a named method. Without those four items there is no technical comparison. Price per milligram is incomplete until peptide content is normalised. Two CoAs quoting similar HPLC purity can still differ in counter-ion and water. Request net peptide content or the data to calculate it, then score documentation: raw chromatograms, mass spectra, lot match to the vial, testing-lab identity, and local stock with tracked dispatch. A higher unit price with a complete analytical pack can be the lower experimental cost if it avoids repeating identity work. Related GHRH analogues should be separated. Tesamorelin-class materials, unmodified GRF fragments and CJC-1295-class bioconjugates are different analytes in the detection literature (PMID:34665524). A generic GHRH CoA template for all of them does not document identity. Communication is a quality signal: can the supplier explain DAC versus non-DAC nomenclature chemically, replace a truncated PDF, and match invoice lot numbers to vials? ClaraScience supplies CJC-1295 as a characterised laboratory reagent with batch documentation. It is not a medicine. Nothing in the analytical file is a human or veterinary use instruction. Purchase against this checklist and retain the file with the lot.
Order Cjc 1295 with documentation
If this guide helped you evaluate Cjc 1295 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Cjc 1295 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is CJC-1295 the same material as tetrasubstituted GRF(1-29)?
Not necessarily. Peer-reviewed identification treats CJC-1295 as an hGRF(1-29)–albumin bioconjugate, whereas tetrasubstituted GRF(1-29) without a conjugation handle is a different intact mass and HPLC peak. A supplier should declare the construct, theoretical mass and observed deconvoluted mass for the lot. Catalogue synonyms are not identity tests. Research use only.
Which CoA fields matter most when comparing Australian CJC-1295 suppliers?
Prioritise lot-number match to the vial, an HPLC chromatogram with method parameters, intact-mass or LC-MS identity, counter-ion, water or net peptide content, the testing laboratory’s name, and tracked dispatch from local Australian stock. A lone purity percentage cannot support a supplier comparison because area-percent is method-defined and ignores peptide content. Keep the material in a research-only file.
Why is HPLC purity alone insufficient to confirm CJC-1295 identity?
HPLC area-percent characterises the main ultraviolet peak under one method; it does not prove sequence or the presence of a conjugation handle. Deletion sequences and related GHRH analogues can look similar until intact mass and fragment ions are inspected. Published confirmatory work on CJC-1295 uses chromatographic retention plus mass-spectrometric transitions rather than a single detector response.
Does a similar purity figure mean two CJC-1295 lots are interchangeable?
No. Counter-ion load, water content, related-substance profile, or an undocumented switch between a maleimide-bearing construct and a non-conjugated GRF(1-29) analogue can leave HPLC purity unchanged while the chemical definition changes. Compare method identifiers, observed masses and net peptide content before treating lots as equivalent research reagents.
Must a research CoA reproduce published plasma detection methods?
No. Immunoaffinity enrichment, immuno-PCR screens and matrix LC-MS/MS methods show how the analyte is distinguished in complex samples. A research CoA should instead provide lot-matched HPLC and mass-spectrometric data for the solid, with method parameters. Those reagent-scale data occupy the confirmatory tier; ultraviolet purity alone occupies the screening tier.
References
- PMID:15817669 — Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Endocrinology — 2005
- PMID:21204297 — Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation — Drug Test Anal — 2010
- PMID:21871962 — Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls — Methods — 2012
- PMID:30489688 — An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma — Drug Test Anal — 2019
- PMID:30938069 — A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS — Drug Test Anal — 2019
- PMID:34665524 — Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal — 2021
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
